{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029500","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2023-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.891806+00:00","generated_at":"2026-06-13T17:54:04.766120+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acasti Pharma reports FY2023 net loss of $42.4M, focuses on GTX-104 Phase 3","bullets":["Net loss of $42.4M ($0.95 loss per share) vs $9.8M loss prior year; impairments of $33.5M.","Cash, cash equivalents and short-term investments $27.9M, expected to fund through Q2 2025 for potential NDA filing.","FDA confirmed 505(b)(2) pathway for GTX-104; Phase 3 Safety Study protocol submitted, first patient H2 2023.","Strategic realignment: R&D focus solely on GTX-104, evaluating partnerships for GTX-102/GTX-101.","R&D expenses $9.9M (up 77% YoY); G&A expenses reduced to $7.6M; restructuring with layoffs in Canada."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029500","json":"https://secwatch.observer/filing/0000950170-23-029500.json","markdown":"https://secwatch.observer/filing/0000950170-23-029500.md","text":"https://secwatch.observer/filing/0000950170-23-029500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/0000950170-23-029500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/acst-20230623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:54:04.766120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34742aec7c77f651189d4aac55a24422270e30b7","claim":"Grace Therapeutics, Inc. reported the fiscal year ended March 31, 2023 results: net income $(42.4) million, EPS $(0.95) loss per share.","evidence_excerpt":"Net loss and total comprehensive loss for the twelve months ended March 31, 2023 was $(42.4) million, or $(0.95) loss per share, compared to a net loss of $(9.8) million, or $(0.27) income per share, for the twelve months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/0000950170-23-029500-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended March 31, 2023"},{"label":"Net income","value":"$(42.4) million"},{"label":"EPS","value":"$(0.95) loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}